Schering Corporation

Merck Sharp + Dohme Corp.

Albany Molecular Research, Inc.

Pharmacopeia Drug Discovery, Inc.

Jianhua Cao

Pauline C Ting

Neng-Yang Shih

Robert G Aslanian

Kevin D McCormick

Stuart B Rosenblum

Daniel M Solomon

Rongze Kuang

Qingbei Zeng

Michael Berlin

Heping Wu

John J Baldwin

Ge Li

Ying Huang

Christopher W Boyce

Wing C Tom

Pietro Mangiaracina

Nicolas Zorn

Gang Zhou

Mwangi W Mutahi

Henry A Vaccaro

John H Schwerdt

Jae-Hun Kim

Joe F Lee

Mwangi Wa Mutahi

Joseph A Kozlowski

Amjad Ali

Stuart W McCombie

Dong Xiao

David J Blythin

Joseph Michael Kelly

Michael Man-Chu Lo

Ho-Jane Shue

Eric J Gilbert

Purakkattle J Biju

Tin-Yau Chan

Li Xiao

Timothy J Henderson

Xiao Chen

Yeon-Hee Lim

Manuel De Lera Ruiz

Robert Jason Herr

Tao Yu

Jayaram R Tagat

Tanweer A Khan

Yonglian Zhang

Xiaohong Zhu

Mary Ann Caplen

Hyunjin M Kim

Youhao Dong

David Kim

Jie Wu

Sylvia Joanna Degrado

Shing-Chun C Wong

Liwu Hong

Jinhai Yang

Danlin Gu

Alexander L Tung

Dong Won-Shik Kim

David Won-Shik Kim

Andrew John Zych

Yushi Xiao

Kevin D Mc Cormick

Michael Y Berlin

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ('DGAT') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: 

Inhibitors of diacylglycerol acyltransferase

Disclosed is a set of compounds useful as glucan synthase inhibitors having the generic structure of Formula I: wherein the various moieties A, D, R, etc., are as defined in the specification. These compounds are useful in treating or preventing fungal infections in a patient.

Pyridazinone derivatives useful as glucan synthase inhibitors

The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, R, X, X, R, R, R, R, R, Rand n are as defined in the specification.

Bipiperdine derivatives useful as CCR3 antagonists

The invention claims compounds of the formula wherein 

Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors

Disclosed are novel compounds of the formula  Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a Hreceptor antagonist.

Piperidine compounds

Disclosed are novel compounds of the formula wherein Ris benzimidazolone derivative, Mand Mare optionally substituted carbon or nitrogen, Rincludes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Disclosed are novel compounds of the formula wherein Ris optionally substituted benzimidazolyl or a derivative thereof; Ris optionally substituted aryl or heteroaryl; Mand Mare C(R) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Benzimidazole derivatives useful as histamine H3 antagonists

Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.

Growing community of inventors

Edison, NJ, United States of America

Jianhua Cao